As of 3:59pm ET
| +0.08 / +1.95%|
The 2 analysts offering 12-month price forecasts for Cascadian Therapeutics Inc have a median target of 11.50, with a high estimate of 13.00 and a low estimate of 10.00. The median estimate represents a +175.12% increase from the last price of 4.18.
The current consensus among 3 polled investment analysts is to Buy stock in Cascadian Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.